PL3862010T3 - Zastosowanie akkermansia muciniphila w promowaniu utraty masy ciała - Google Patents

Zastosowanie akkermansia muciniphila w promowaniu utraty masy ciała

Info

Publication number
PL3862010T3
PL3862010T3 PL21154064.6T PL21154064T PL3862010T3 PL 3862010 T3 PL3862010 T3 PL 3862010T3 PL 21154064 T PL21154064 T PL 21154064T PL 3862010 T3 PL3862010 T3 PL 3862010T3
Authority
PL
Poland
Prior art keywords
weight loss
akkermansia muciniphila
promote weight
promote
muciniphila
Prior art date
Application number
PL21154064.6T
Other languages
English (en)
Inventor
Patrice Cani
Amandine EVERARD
Clara BELZER
Willem De Vos
Original Assignee
Université Catholique de Louvain
Wageningen Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47257788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3862010(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Université Catholique de Louvain, Wageningen Universiteit filed Critical Université Catholique de Louvain
Publication of PL3862010T3 publication Critical patent/PL3862010T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
PL21154064.6T 2012-11-19 2013-11-15 Zastosowanie akkermansia muciniphila w promowaniu utraty masy ciała PL3862010T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/073011 WO2014075745A1 (en) 2012-11-19 2012-11-19 Use of akkermansia for treating metabolic disorders

Publications (1)

Publication Number Publication Date
PL3862010T3 true PL3862010T3 (pl) 2025-08-25

Family

ID=47257788

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21189951.3T PL3967315T3 (pl) 2012-11-19 2013-11-15 Akkermansia muciniphila do leczenia nowotworu złośliwego
PL21154064.6T PL3862010T3 (pl) 2012-11-19 2013-11-15 Zastosowanie akkermansia muciniphila w promowaniu utraty masy ciała

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL21189951.3T PL3967315T3 (pl) 2012-11-19 2013-11-15 Akkermansia muciniphila do leczenia nowotworu złośliwego

Country Status (14)

Country Link
US (10) US20150306152A1 (pl)
JP (2) JP6426616B2 (pl)
KR (7) KR20250048486A (pl)
CN (2) CN111603488B (pl)
AU (1) AU2013346726B2 (pl)
BR (1) BR112015011403A2 (pl)
CA (1) CA2891758C (pl)
DK (1) DK2919796T3 (pl)
EA (2) EA202100040A3 (pl)
ES (3) ES3038019T3 (pl)
MX (1) MX365835B (pl)
PL (2) PL3967315T3 (pl)
PT (1) PT2919796T (pl)
WO (2) WO2014075745A1 (pl)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CN110201003A (zh) 2012-02-29 2019-09-06 伊西康内外科公司 微生物区系的组合物及与其相关的方法
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10633714B2 (en) 2013-07-21 2020-04-28 Pendulum Therapeutics, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US20150246081A1 (en) * 2014-03-03 2015-09-03 Shayne Kenneth Morris Probiotics with methods for growth and use separately and in combination
KR101740893B1 (ko) 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
CN113730442A (zh) * 2014-10-31 2021-12-03 潘德勒姆治疗公司 与病症的微生物治疗和诊断有关的方法和组合物
LT3065748T (lt) 2014-12-23 2018-03-12 4D Pharma Research Limited Bacteroides thetaiotaomicron padermė ir jos panaudojimas uždegimo sumažinimui
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
US10988509B2 (en) 2015-05-06 2021-04-27 Wageningen Universiteit Method of culturing Akkermansia
AU2016257315A1 (en) * 2015-05-06 2017-11-23 Université Catholique de Louvain Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PL3307288T3 (pl) 2015-06-15 2019-12-31 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
SMT202200174T1 (it) 2015-06-15 2022-05-12 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SG10201912323VA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
CN105106245A (zh) * 2015-08-24 2015-12-02 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
CN105030841A (zh) * 2015-08-24 2015-11-11 上海交通大学医学院附属瑞金医院 Akkermansia muciniphila BAA-835菌株的应用
DK3626081T3 (da) * 2015-09-10 2022-02-28 Univ Catholique Louvain Pasteuriseret akkermansia til fremme af vægttab
EP3359171B1 (en) * 2015-10-05 2023-07-05 Schweizerisches Forschungsinstitut für Hochgebirgsklima und Medizin in Davos Use of akkermansia muciniphila for treating inflammatory conditions
WO2017060491A1 (en) * 2015-10-09 2017-04-13 Biogaia Ab Mucus thickness to prevent diseases
CN105176822B (zh) * 2015-10-23 2019-01-11 广州康泽医疗科技有限公司 一种人类肠道益生菌的优化分离方法
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP7016112B2 (ja) 2016-02-04 2022-02-04 ユニベルシテイト ゲント ヒトおよび動物の健康ための微生物コミュニティーの使用
GB2557823A (en) * 2016-03-04 2018-06-27 Univ California Microbial consortium and uses thereof
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
US11202807B2 (en) * 2016-04-11 2021-12-21 Wageningen Universiteit Bacterial species
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3483256A4 (en) * 2016-07-11 2019-12-04 Korea Research Institute of Bioscience and Biotechnology AKKERMANSIA MUCINIPHILA TRIBE WITH EFFECT FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES OR METABOLIC DISEASES AND USE THEREOF
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
CN109874329B (zh) * 2016-08-12 2023-08-29 深圳华大生命科学研究院 一种产丁酸栖粪杆菌及其培养方法和应用
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
JP7166280B2 (ja) * 2016-12-20 2022-11-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発作を抑制する組成物及び方法
WO2018187272A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
FR3065643B1 (fr) 2017-04-26 2020-04-17 Usines Chimiques D'ivry La Bataille (Ucib) Composition nutraceutique et/ou pharmaceutique pour stimuler la production de beta-defensines de type 2
US10695386B2 (en) 2017-05-11 2020-06-30 Shayne K. Morris Skin microbiome colonizer formulations and methods for use
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
MA49373B1 (fr) 2017-06-14 2021-02-26 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
MA49425A (fr) 2017-06-14 2020-04-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI640314B (zh) * 2017-08-22 2018-11-11 長庚生物科技股份有限公司 戈氏副擬桿菌用於降低胰島素抗性及提升葡萄糖耐受性之用途
TWI636788B (zh) * 2017-08-28 2018-10-01 長庚生物科技股份有限公司 戈氏副擬桿菌用於抑制脂肪肝疾病之用途
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
JP7171602B2 (ja) * 2017-11-08 2022-11-15 アサヒグループホールディングス株式会社 アッカーマンシア・ムシニフィラ増殖材
EP3716983A4 (en) * 2017-11-30 2022-03-02 Glycom A/S HUMAN MILK OLIGOSACCHARIDES AND SYNTHETIC COMPOSITIONS THEREOF FOR MICROBIOTA MODULATION
EP3758721B1 (en) * 2018-03-02 2022-05-18 Academisch Medisch Centrum Fecal matter for prevention or treatment of autoimmune diseases
WO2019199895A1 (en) 2018-04-10 2019-10-17 Siolta Therapeutics, Inc. Microbial consortia
US11168299B2 (en) 2018-04-11 2021-11-09 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
US11291696B2 (en) 2018-04-11 2022-04-05 Shayne Morris Pairing probiotics and prebiotics, methods for growth and use, separately and in combination
KR102225939B1 (ko) * 2018-04-19 2021-03-10 주식회사 고바이오랩 신규한 Bacteroides vulgatus 균주 및 이를 유효 성분으로 하는 면역 및 대사성 질환 예방 또는 치료용 조성물
JP7557777B2 (ja) * 2018-05-15 2024-09-30 デューク ユニバーシティ アッカーマンシア種の遺伝子操作のためのシステムおよび方法
CN110496140B (zh) * 2018-05-18 2022-05-31 瑞微（深圳）生物科技有限公司 脆弱拟杆菌或阿克曼粘细菌在制备用于预防或治疗肿瘤的药物中的应用
WO2019226723A1 (en) * 2018-05-23 2019-11-28 The Regents Of The University Of California Methods of selecting subjects for treatment with metabolomic modulators
EP3594321A1 (en) * 2018-07-10 2020-01-15 Université catholique de Louvain Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
AU2019306649A1 (en) 2018-07-19 2021-02-04 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
CA3109264A1 (en) * 2018-08-20 2020-02-27 Murdoch Children's Research Institute Behavioural treatment
CN110964650B (zh) 2018-09-27 2022-10-11 上海上药信谊药厂有限公司 一种用于预防和治疗代谢疾病的菌株及其应用
WO2020071660A1 (ko) * 2018-10-01 2020-04-09 한국생명공학연구원 아커만시아 뮤시니필라 균주 또는 이의 배양물을 유효성분으로 함유하는 노화방지용 조성물
KR102197180B1 (ko) * 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
WO2020076136A2 (ko) * 2018-10-11 2020-04-16 서울대학교산학협력단 아커만시아 뮤시니필라 균주 및 이의 용도
EP3669944B1 (en) * 2018-12-21 2023-12-20 Salomon Amar Use of akkermansia in the treatment of oral diseases
CN114450399A (zh) * 2019-05-02 2022-05-06 卢万天主教大学 用于治疗癌症的乳酸脱氢酶抑制剂多肽
JP7402629B2 (ja) * 2019-07-19 2023-12-21 国立大学法人東京農工大学 プロピオン酸菌発酵物含有組成物
TWI719549B (zh) * 2019-07-22 2021-02-21 大江生醫股份有限公司 促進嗜黏蛋白艾克曼菌生長之益生質組合物
KR102128287B1 (ko) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 아커만시아 뮤시니필라 eb-amdk19 균주 및 그의 용도
KR102128289B1 (ko) * 2019-08-23 2020-06-30 주식회사 엔테로바이옴 아커만시아 뮤시니필라 eb-amdk27 균주 및 그의 용도
US20240226186A9 (en) * 2019-09-25 2024-07-11 Healthbiome Obligate anaerobic human intestinal microbe for cancer treatment, and use thereof
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
JP7624449B2 (ja) 2019-10-07 2025-01-30 シオルタ・セラピューティクス，インコーポレイテッド 治療用医薬組成物
CN110698547B (zh) * 2019-10-31 2023-01-03 南京农业大学 重组表达的阿克曼菌膜蛋白Amuc_1100及其应用
CN110786376A (zh) * 2019-11-07 2020-02-14 中南大学湘雅医院 嗜黏蛋白艾克曼氏灭活菌在制备酸奶中的应用及酸奶的制备方法和应用
CN111202752A (zh) * 2020-02-17 2020-05-29 上海市内分泌代谢病研究所 阿克曼氏菌组合物
CN118340799A (zh) 2020-02-27 2024-07-16 上海上药信谊药厂有限公司 抗肿瘤组合物
CN111450233B (zh) * 2020-03-19 2021-04-13 中国农业大学 一种微生物代谢产物在缓解糖脂代谢紊乱中的应用
KR102671044B1 (ko) * 2020-03-25 2024-05-31 한국생명공학연구원 아커만시아 뮤시니필라 유래의 tars 또는 이의 단편 및 이의 용도
JP2023542447A (ja) * 2020-04-03 2023-10-10 デュポン ニュートリション バイオサイエンシス エーピーエス 代謝の健康を改善するための細菌株を含む組成物
WO2021215828A1 (ko) * 2020-04-24 2021-10-28 주식회사 고바이오랩 Glp-1 유도 활성을 갖는 단백질 변이체 및 이의 용도
CN111996267A (zh) * 2020-08-11 2020-11-27 康美华大基因技术有限公司 一种快速检测akk菌的荧光定量pcr引物组、试剂盒及其应用
KR102185827B1 (ko) * 2020-08-26 2020-12-03 주식회사 엔테로바이옴 아커만시아 뮤시니필라 균주를 포함하는 아토피성 질환 예방 또는 치료용 약학적 조성물
BE1028339B1 (fr) * 2020-11-09 2021-12-21 A Mansia Biotech Composition comprenant de l'Akkermansia muciniphila et de l'extrait de thé vert
CN113116936A (zh) * 2021-04-02 2021-07-16 上海市第六人民医院 嗜黏蛋白艾克曼氏菌在制备β-鹅脱氧胆酸抑制剂中的应用
CN113322202B (zh) * 2021-05-31 2022-03-01 君维安(武汉)生命科技有限公司 一种阿克曼氏菌、其培养方法及其应用
KR102380194B1 (ko) * 2021-06-11 2022-03-29 쿼럼바이오 주식회사 갈락토오스를 포함하는 장내 미생물 개체군 개선용 조성물
JP7398714B2 (ja) * 2021-06-28 2023-12-15 東栄新薬株式会社 医療・美容に応用可能なアッカーマンシア・ムシニフィラ増殖促進用組成物およびこれを含む医薬、飲食品、飼料
CN113862193B (zh) * 2021-10-28 2023-12-22 江西普瑞森基因科技有限公司 一株嗜黏蛋白阿克曼氏菌及其在制备抗肿瘤药物中的应用
KR20250083399A (ko) * 2021-11-12 2025-06-10 젤레시스 엘엘씨 장내 마이크로바이옴 조절을 위한 조성물 및 방법
AU2023234546A1 (en) * 2022-03-15 2024-09-05 Pendulum Therapeutics, Inc. Novel microbial composition and methods of use thereof
CN114634892B (zh) * 2022-03-24 2024-07-26 浙江省农业科学院 具有降血脂作用的益生菌组合物、制备方法及设备
CN116115647B (zh) * 2022-06-08 2024-12-20 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备改善代谢综合征的药物组合物或保健品组合物中的应用
CN115252651B (zh) * 2022-06-08 2024-06-07 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备防治高血压的组合物中的应用和含有其的组合物
CN114949002B (zh) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌在制备防治动脉粥样硬化的组合物中的应用
CN114949003B (zh) * 2022-06-08 2024-03-19 广州知易生物科技有限公司 嗜粘蛋白阿克曼菌及其应用和培养方法
CN115804793B (zh) * 2022-06-08 2025-08-15 石家庄普维生物科技有限公司 嗜粘蛋白阿克曼菌在制备改善酒精性肝功能异常的组合物中的应用、组合物及应用
CN115463159A (zh) * 2022-09-26 2022-12-13 暨南大学附属第一医院（广州华侨医院） 一种阿克曼菌及阿克曼菌后生元在制备预防或治疗肝脏脂肪病变的药物或保健品中的应用
CN115747357A (zh) * 2022-11-15 2023-03-07 迪辅乐生物(上海)有限公司 肠道嗜粘蛋白-阿克曼氏菌的检测试剂盒及其检测方法
WO2024134035A1 (fr) * 2022-12-22 2024-06-27 Sorbonne Universite Composition et utilisation de turicimonas muris pour le traitement de maladies métaboliques
CN116077536B (zh) * 2023-03-17 2023-11-28 微康益生菌(苏州)股份有限公司 一种用于改善肥胖相关代谢疾病的微生态活菌制剂及其制备方法和应用
CN116999468B (zh) * 2023-08-18 2024-11-15 善恩康生物科技（苏州）有限公司 Akkermansia muciniphila在制备预防、治疗和/或辅助治疗心血管疾病的产品中的应用
WO2025042949A2 (en) * 2023-08-22 2025-02-27 International N&H Denmark Aps Methods and compositions for immune system regulation
CN117603884B (zh) * 2024-01-17 2024-03-26 广州同康生物科技有限公司 一种嗜黏蛋白阿克曼氏菌菌粉及其制备方法
CN118178476A (zh) * 2024-04-03 2024-06-14 暨南大学附属第一医院（广州华侨医院） 阿克曼菌及其制剂在制备促进排便、排脂、减少肠道脂肪吸收的药物中的应用
CN118207140B (zh) * 2024-05-20 2024-09-17 微康益生菌(苏州)股份有限公司 一种具有调节血糖血脂功效的嗜粘蛋白阿克曼氏菌Akk11及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) * 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
EP2103226A1 (en) * 2008-03-18 2009-09-23 Friesland Brands B.V. Long-life probiotic food product
JP2013520972A (ja) 2010-03-01 2013-06-10 アンスティテュ ナシオナル ドゥ ラ ルシェルシュ アグロノミック 炎症性腸疾患の診断方法
CN110201003A (zh) * 2012-02-29 2019-09-06 伊西康内外科公司 微生物区系的组合物及与其相关的方法
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders

Also Published As

Publication number Publication date
JP2016503418A (ja) 2016-02-04
CN104918626A (zh) 2015-09-16
CN111603488B (zh) 2024-04-05
US20150306152A1 (en) 2015-10-29
DK2919796T3 (da) 2021-05-31
US20210393704A1 (en) 2021-12-23
US20200237833A1 (en) 2020-07-30
KR20240137696A (ko) 2024-09-20
ES3038019T3 (en) 2025-10-08
KR20150093711A (ko) 2015-08-18
US20210322489A1 (en) 2021-10-21
EA201500535A1 (ru) 2016-03-31
ES2871817T3 (es) 2021-11-02
KR20230080492A (ko) 2023-06-07
CN111603488A (zh) 2020-09-01
EA037315B1 (ru) 2021-03-11
US20200237832A1 (en) 2020-07-30
EA202100040A3 (ru) 2021-10-29
KR20210111871A (ko) 2021-09-13
PL3967315T3 (pl) 2025-10-20
HK1215375A1 (zh) 2016-08-26
WO2014075745A1 (en) 2014-05-22
AU2013346726A1 (en) 2015-06-04
KR20250049431A (ko) 2025-04-11
MX2015006234A (es) 2015-10-29
JP6426616B2 (ja) 2018-11-21
BR112015011403A2 (pt) 2018-02-06
MX365835B (es) 2019-06-17
KR102581171B1 (ko) 2023-09-21
US20190282630A1 (en) 2019-09-19
JP2019048825A (ja) 2019-03-28
CA2891758C (en) 2022-06-07
US20250288622A1 (en) 2025-09-18
PT2919796T (pt) 2021-06-02
EA202100040A2 (ru) 2021-06-30
US20200121737A1 (en) 2020-04-23
CA2891758A1 (en) 2014-05-22
ES3037446T3 (en) 2025-10-02
US20200155616A1 (en) 2020-05-21
CN104918626B (zh) 2020-07-07
KR20230121938A (ko) 2023-08-21
WO2014076246A1 (en) 2014-05-22
KR20250048486A (ko) 2025-04-08
KR102297388B9 (ko) 2025-04-01
US20250288621A1 (en) 2025-09-18
AU2013346726B2 (en) 2017-11-02
KR102297388B1 (ko) 2021-09-03

Similar Documents

Publication Publication Date Title
PL3862010T3 (pl) Zastosowanie akkermansia muciniphila w promowaniu utraty masy ciała
PT2878018T (pt) Resumo
PT2819623T (pt) Resumo
EP2763896A4 (en) UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS
DK2859055T3 (da) Polymercoatings
DK2825087T3 (da) Otoscanner
EP2809145A4 (en) CHLOROPLAST TRANSIT PEPTIDES
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
EP2814472A4 (en) DITHIOAMINE REDUCING AGENTS
EP2824794A4 (en) Charging cable
EP2805877A4 (en) UNDER HOOD
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DK2854722T3 (da) Stomipose
PT2831109T (pt) Resumo
EP2816694A4 (en) FLAT CABLE WINDING DEVICE
DK2880228T3 (da) Stilladsstruktur
DK2825157T3 (da) Aminosyrelipider
EP2809729A4 (en) Siloxane polyether copolymers
EP2801315A4 (en) SCANNING ENDOSCOPE DEVICE
DE112012006214T8 (de) Wulstringwickler
DK2831122T3 (da) Anthocyanidin-kompleks
DK2923109T3 (da) Svinghjul
PL2900676T3 (pl) Ulepszony sposób acylowania majtansynolu
BR302013000072S1 (pt) Configuração aplicada em empilhadeira